Pharmacists and Biosimilars

Pharmacists are well positioned to help oversee the integration of biosimilars into patient care. Pharmacists have the opportunity to educate providers and patients about the biosimilar landscape and help implement an efficient workflow to support biosimilar adoption and use.

This resource center provides pharmacists with meaningful information and resources that will allow them to better understand biosimilars, their economic impact, as well as how to better implement biosimilars in therapeutic areas within various practice settings.

Think you're a biosimilars pro?

Let’s find out! Surprisingly many healthcare professionals know less than they think about biosimilars. Test your knowledge with this quick quiz.

Resource News

Take note of recently added and upcoming resources.

On-demand Webinar

Biosimilar Adoption: Past Experiences and Future Opportunities

Engaging the Experts: A New Landscape: Biosimilars in Multiple Sclerosis

Learn from experts in the field on Multiple Sclerosis.

Accelerating the Adoption of Biosimilars

A recent report that was part of an ASHP and ASHP Foundation project, Accelerating the Adoption of Biosimilars, explored biosimilars’ current and future adoption in the United States.

Biosimilars by the Numbers

91%

of U.S. prescriptions filled by generic drugs
$373 B

in U.S. health care system savings
$6.16

the average generic drug copay
$7 B

plus in savings from the use of biosimlars
$119 B

in Medicare savings attributed to generics and biosimilars
91%

of U.S. prescriptions filled by generic drugs
$373 B

in U.S. health care system savings
$6.16

the average generic drug copay
$7 B

plus in savings from the use of biosimlars
$119 B

in Medicare savings attributed to generics and biosimilars
91%

of U.S. prescriptions filled by generic drugs
$373 B

in U.S. health care system savings
$6.16

the average generic drug copay
$7 B

plus in savings from the use of biosimlars
$119 B

in Medicare savings attributed to generics and biosimilars
91%

of U.S. prescriptions filled by generic drugs
$373 B

in U.S. health care system savings

Rheumatology Biosimilars Landscape

In 2023, several adalimumab biosimilars from different manufacturers are anticipated to enter the US market for patient use. Adalimumab biosimilars have several unique considerations, such as interchangeability and concentration, that will impact pharmacy practices and workflows. Understanding the various adalimumab biosimilar products available and considerations surrounding these products with regard to workflow and patient use is critical.

More information

Multiple Sclerosis Biosimilars Landscape

Natalizumab was approved in 2004 for the treatment of patients with relapsing forms of multiple sclerosis (MS) and in 2008 to treat moderate-to-severe-Crohn’s disease. In July 2022 the Food and drug Administration (FDA) accepted a Biologics License Application (BLA) for a proposed biosimilar to natalizumab.

More information

2023 Biosimilars Report

Recent report looks prescriber trends for rheumatology, gastroenterology, dermatology, adalimumab biosimilars, and ophthalmology. It also looks ahead to new and upcoming biosimilars launches, and the adalimumab biosimilars pipeline

More information

The U.S. Generic & Biosimilar Medicines Savings Report

Published in 2022 by the Association for Accessible Medications. The report leads with, "Savings From Generics and Biosimilars Continue To Grow, but Face Future Headwinds. More than $2.6 trillion in savings from medications used to treat nearly every health condition."

More information